Skip to main content
Year archive

TiumBio Co., Ltd. — 2024 filings

All 48 regulatory filings released by TiumBio Co., Ltd. (321550) in 2024, sourced directly from the official regulator.

48 Filings
2024 Period
2024 filings (48)
Filing Released Lang
합병등종료보고서(합병)
M&A Activity
2024-12-27 Korean
합병등종료보고서(자산양수도)
M&A Activity
2024-12-26 Korean
전환가액의조정
Share Issue/Capital Change
2024-12-23 Korean
투자판단관련주요경영사항(임상시험결과) (혈우병 치료신약 TU7710의 임상 1a상 Topline 결과 발표)
Legal Proceedings Report
2024-12-23 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings
2024-12-16 Korean
기업설명회(IR)개최
Report Publication Announcement
2024-12-04 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update
2024-12-02 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity
2024-11-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2024-11-20 Korean
기업설명회(IR)개최
Report Publication Announcement
2024-11-15 Korean
주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity
2024-11-15 Korean
분기보고서 (2024.09)
Interim / Quarterly Report 9M 2024
2024-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2024-11-11 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings
2024-10-28 Korean
[첨부추가]주요사항보고서(회사합병결정)
M&A Activity
2024-10-28 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update
2024-09-02 Korean
반기보고서 (2024.06)
Interim / Quarterly Report H1 2024
2024-08-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (혈우병 치료신약 TU7710의 유럽 임상 1b상 시험계획(IND) 승인)
Legal Proceedings Report
2024-07-16 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update
2024-05-31 Korean
전환가액의조정
Share Issue/Capital Change
2024-05-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2024-05-21 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Q1 2024
2024-05-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification
2024-05-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2024-05-10 Korean
투자판단관련주요경영사항(임상시험결과) (TU2670 (INN: merigolix, 메리골릭스)의 자궁내막증 유럽 임상 2a상 Top-line 결과 발표)
Legal Proceedings Report
2024-05-07 Korean
기업설명회(IR)개최
Report Publication Announcement
2024-05-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2024-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2024-04-19 Korean
투자판단관련주요경영사항(임상시험계획변경승인) (면역항암제 TU2218 식약처 임상1/2상 임상시험계획 변경승인)
Regulatory Filings
2024-04-17 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements
2024-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information
2024-03-28 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (혈우병 치료신약 TU7710 의 유럽 임상 1b상 시험계획(IND) 승인신청)
Legal Proceedings Report
2024-03-20 Korean
사업보고서 (2023.12)
Annual Report FY 2023
2024-03-20 Korean
감사보고서제출
Audit Report / Information FY 2023
2024-03-20 Korean
주주총회소집결의
Proxy Solicitation & Information Statement
2024-03-12 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
주주총회소집공고
AGM Information
2024-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2024-03-12 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update
2024-02-29 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (면역항암제 TU2218 식약처 임상1/2상 임상시험계획 변경승인 신청)
Regulatory Filings
2024-02-23 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release FY 2023
2024-02-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification
2024-01-02 Korean